Loading...
Loading...
SGEN| Name | Value |
|---|---|
| Revenues | 648.6M |
| Cost of Revenue | 165.3M |
| Gross Profit | 483.4M |
| Operating Expense | 714.7M |
| Operating I/L | -231.3M |
| Other Income/Expense | 15.0M |
| Interest Income | 14.5M |
| Pretax | -216.4M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -215.8M |
Seagen Inc. is a biotechnology company specializing in the development and commercialization of cancer therapies. The company's primary revenue-generating products include ADCETRIS, PADCEV, and TUKYSA, which are antibody-drug conjugates targeting specific cancer types. Additionally, Seagen Inc. is actively developing other potential treatments such as TIVDAK, Ladiratuzumab Vedotin, Disitamab Vedotin, and various other compounds for different cancer diseases. The company also has collaboration agreements with several pharmaceutical companies. Seagen Inc. generates revenue through the sale of its cancer therapies and through collaboration and licensing agreements with partners.
